Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)



Status:Recruiting
Conditions:Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 70
Updated:3/30/2013
Start Date:September 2011
Contact:Study Manager
Email:cami.stewart@ppdi.com
Phone:561-573-9403

Use our guide to learn which trials are right for you!

An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis


This is an open-label, 26-week safety and efficacy study in subjects with spasticity due to
MS who have completed the XP-B-089 Study, and also includes an addendum open-label, 36-week
safety study in subjects with spasticity due to MS who have not participated in the XP-B-089
study to assess the long-term safety and efficacy of arbaclofen placarbil in subjects with
spasticity due to MS.


Primary Study Inclusion:

1. Subjects who have successfully completed study XP-B-089.

2. If a subject is on disease modifying MS treatment, the dosage, frequency, and route
of administration must have remained stable for the duration of study XP-B-089.

3. Willing to continue to refrain from using for the duration of the study drugs for the
treatment of spasticity or likely to affect spasticity including, but not limited to,
baclofen, tizanidine, diazepam, clonazepam, metaxalone, dantrolene, cyclobenzaprine,
carisoprodol, clonidine, vigabatrin, valproic acid, and cannabis (refer to Appendix
2, Prohibited Concomitant Medications).

Primary Study Exclusion:

1. Scheduled elective surgery or other procedures requiring general anesthesia during
the study.

2. Subjects who, in the opinion of the Investigator, would be non-compliant with the
study visit schedule, procedures, or medication administration.

3. Subjects who have an unstable or clinically significant medical or psychiatric
illness that, in the opinion of the Investigator, could confound the collection of
meaningful safety data or pose a risk to the subject.

4. Treatment with botulinum toxin products, phenol, or alcohol injections during or
subsequent to the previous study XP-B-089, or plans to receive these treatments
during the time period of study XP-B-091

Addendum Study Inclusion:

1. Has multiple sclerosis (MS) based on Poser or McDonald Criteria (all subtypes of MS
will be accepted, including relapsing remitting, primary or secondary progressive, if
disease is stable per exclusion criteria).

2. Expanded Disability Status Scale (EDSS) rating between 3.0-8.0 inclusive

3. Spasticity Disability Rating of 2 or higher at Screening

4. If a subject is on disease modifying MS treatment, the dosage, frequency, and route
of administration must be stable for at least 30 days before screening and is
expected to be stable throughout the study.

5. Willing to discontinue and refrain from using for the duration of the study drugs for
the treatment of spasticity or likely to affect spasticity (including, but not
limited to, baclofen tizanidine, diazepam, clonazepam, metaxalone, dantrolene,
cyclobenzaprine, carisoprodol, clonidine, vigabatrin, valproic acid and cannabis).

Addendum Study Exclusion:

1. Spasticity due to neurological disorder other than MS or other conditions that may
confound the assessment of spasticity.

2. Subject has clinically evident muscle contractures resulting in irreversible
spasticity in lower extremities.

3. Subjects who have suffered an acute relapse of MS (as determined by the Investigator)
within 90 days prior to Screening, or have had more than 1 relapse within the year
prior to Screening.

4. Subjects receiving concomitant medication from more than one of the following three
drug classes: (Antiepileptic drugs, Tricyclic anti-depressants and Opioids)

5. At the start, subjects on the following medications, at doses above the specified
limits, are excluded if they cannot maintain a level within these limits:

- Gabapentin ≤ 1800 mg per day or pregabalin ≤ 150 mg per day

- Amitriptyline ≤ 75 mg per day or nortriptyline ≤ 75 mg per day

- Opioids ≤ 30 mg morphine equivalents per day.

6. Botulinum toxin, phenol, or alcohol injections within 6 months of screening.
We found this trial at
18
sites
Phoenix, Arizona 85013
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Asheville, North Carolina
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Bingham Farms, Michigan 48025
?
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Franklin, Tennessee
?
mi
from
Franklin, TN
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Kansas 66160
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Lake Barrington, Illinois
?
mi
from
Lake Barrington, IL
Click here to add this to my saved trials
Lexington, Kentucky
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Long Beach, California 90806
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Naples, Florida 34102
?
mi
from
Naples, FL
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Seattle, Washington
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Vienna, Virginia
?
mi
from
Vienna, VA
Click here to add this to my saved trials